Investing in stocks remains one of the best ways to accumulate capital over long periods. Companies that can last -- and ...
A clinical trial involving individuals genetically predisposed to develop early-onset Alzheimer’s disease suggests that ...
Through his X handler, Kamath revealed that he has been following the developments around Ozempic and GLP-1 drugs with some ...
The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...
President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC ...
A new study has found faster accumulation of tau -- a key indicator of Alzheimer's disease -- in the brains of women over the age of 70 who took menopausal hormone therapy (HT) more than a decade ...
Zacks Investment Research on MSN11h
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage StudyShares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, ...
20hon MSN
Zerodha CEO Nithin Kamath described weight-loss drugs Ozempic and Mounjaro as near 'miracle drugs,' highlighting their ...
Study Finds on MSN4h
The Simple Smell Test That Could Catch Alzheimer’s Disease EarlyIn a nutshell A simple at-home smell test, the AROMHA test, could help detect early signs of Alzheimer’s disease years before ...
Semaglutide, branded as Rybelsus, Wegovy or Mounjaro, most popularly identified by Ozempic (as branded by Danish pharma giant ...
GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...
Stockhead on MSN17h
Top of mind: ASX companies tackling neurological disordersSeveral ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback